Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
Launched by CHANG GUNG MEMORIAL HOSPITAL · Jan 20, 2024
Trial Information
Current as of June 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare two types of imaging tests, 68Ga-FAPI-46 and 18F-FDG PET/CT scans, to see which one is better at finding recurring tumor lesions in women who have had ovarian cancer. The study is specifically looking at women aged 30 to 80 who have shown a complete response to their initial treatment but have seen a rise in a specific blood marker called CA125, which can indicate the return of cancer.
To participate, women must have a confirmed diagnosis of ovarian cancer and meet certain health criteria. They should not have any other cancers, and they should be able to lie still for about 30 minutes during the scan. Participants will need to give their consent to join the study and will have the opportunity to receive additional therapy if their cancer is found to be recurring. This study is currently recruiting participants and aims to improve the way doctors detect and manage ovarian cancer recurrence.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pathologically proven ovarian cancer with complete response after therapy
- • Age between 30 and 80
- • Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range
- • ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
- • Willing to enter this prospective study with signed informed consent form
- Exclusion Criteria:
- • Patients with history of other malignancy
- • Patients who are pregnant or lactating
- • Patients with fasting fingerstick glucose level higher than 200 mg/dl
- • Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
- • Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taoyuan City, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported